Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | PDE1A | P54750 | 1/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | LGMN | Q99538 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387340 | 0.81 | ADORA2B (0.55) | PDE2APDE1APDE1BPDE1CMAPT | |
| SCHEMBL5406879 | 0.71 | HPGD (0.56) | PDE2APDE1APDE1BPDE1CMAPT | |
| SCHEMBL515533 | 0.71 | CYP3A4 (0.62) | PDE2APDE1APDE1BPDE1CMAPT | |
| SCHEMBL6381402 | 0.69 | ADORA2B (0.36) | PDE2APDE1APDE1BPDE1CADORA2B | |
| SCHEMBL23607958 | 0.68 | MAPT (0.37) | MAPTALDH1A1HPGDADORA2BADORA2A | |
| SCHEMBL22521968 | 0.68 | CYP2C9 (0.61) | MAPTALDH1A1HPGDKDM4ECYP3A4 | |
| SCHEMBL150604 | 0.67 | PDE1A (0.54) | PDE2APDE1APDE1BPDE1CADORA2B | |
| SCHEMBL461786 | 0.67 | PDE2A (0.62) | PDE2APDE1APDE1BPDE1CALDH1A1 | |
| Water SCHEMBL28799658 | 0.66 | PDE2A (0.60) | PDE2APDE1APDE1BPDE1CALDH1A1 | |
| Theobromine SCHEMBL2328879 | 0.65 | CYP3A4 (0.66) | MAPTALDH1A1ADORA2BADORA2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250386846-A1 | Food Compositions Including Aragonite | NANT HOLDINGS IP LLC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12419336-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250194654-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2025-06-19 | — | — | US | disclosed |
| US-12310392-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240381918-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2024-11-21 | — | — | US | disclosed |
| US-12089621-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230354865-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2023-11-09 | — | — | US | disclosed |
| US-11793224-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230085907-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2023-03-23 | — | — | US | disclosed |
| US-11533940-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2022-12-27 | — | — | US | disclosed |
| EP-1289531-A2 | KITS AND METHODS FOR OPTIMIZING THE EFFICACY OF CHONDROPROTECTIVE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020187219-A1 | Low glycemic response compositions | THE PROCTER & GAMBLE CO. | 2002-12-12 | — | — | US | disclosed |
| US-20020136802-A1 | Beverage compositions comprising arabinogalactan and defined minerals | THE PROCTER & GAMBLE CO. | 2002-09-26 | — | — | US | disclosed |
| US-20020132780-A1 | Low carbohydrate compositions, kits thereof, and methods of use | SD IP HOLDINGS COMPANY | 2002-09-19 | — | — | US | disclosed |
| US-20020122847-A1 | Beverage compositions comprising palatable calcium and magnesium sources | PROCTER & GAMBLE COMPANY, THE | 2002-09-05 | — | — | US | disclosed |
| US-20020110632-A1 | Beverage compositions comprising arabinogalactan and defined vitamins | THE PROCTER & GAMBLE CO. | 2002-08-15 | — | — | US | disclosed |
| US-6413558-B1 | MIXTURE OF MONOSACCHARIDES, DISACCHARIDES AND MALTODEXTRIN | THE PROCTOR & GAMBLE CO. | 2002-07-02 | — | — | US | disclosed |
| WO-2001093832-A2 | AQUEOUS CHONDROPROTECTIVE COMPOSITIONS HAVING DEFINED DOSAGE REQUIREMENTS FOR EFFICACIOUS DELIVERY | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093833-A2 | KITS AND METHODS FOR OPTIMIZING THE EFFICACY OF CHONDROPROTECTIVE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093701-A2 | AQUEOUS CHONDROPROTECTIVE COMPOSITIONS HAVING DEFINED PH LIMITATIONS FOR EFFICACIOUS DELIVERY | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250386846-A1 | Food Compositions Including Aragonite | PLCG2, PLCG1, PLCB3 | PDE2A 3038/4885PDE1A 556/4885PDE1B 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.